HK1221231A1 - Vegf拮抗剂治疗早产儿视网膜病变的用途 - Google Patents

Vegf拮抗剂治疗早产儿视网膜病变的用途 Download PDF

Info

Publication number
HK1221231A1
HK1221231A1 HK16109250.8A HK16109250A HK1221231A1 HK 1221231 A1 HK1221231 A1 HK 1221231A1 HK 16109250 A HK16109250 A HK 16109250A HK 1221231 A1 HK1221231 A1 HK 1221231A1
Authority
HK
Hong Kong
Prior art keywords
vegf antagonist
prematurity
infant
treating retinopathy
retinopathy
Prior art date
Application number
HK16109250.8A
Other languages
English (en)
Chinese (zh)
Inventor
Gabriela BURIAN
Sergey AKSENOV
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of HK1221231A1 publication Critical patent/HK1221231A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B18/00—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
    • A61B18/02—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by cooling, e.g. cryogenic techniques
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F9/00—Methods or devices for treatment of the eyes; Devices for putting in contact-lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
    • A61F9/007—Methods or devices for eye surgery
    • A61F9/008—Methods or devices for eye surgery using laser
    • A61F9/00821—Methods or devices for eye surgery using laser for coagulation
    • A61F9/00823—Laser features or special beam parameters therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Surgery (AREA)
  • Molecular Biology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medical Informatics (AREA)
  • Otolaryngology (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Vascular Medicine (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Endocrinology (AREA)
  • Peptides Or Proteins (AREA)
HK16109250.8A 2013-07-11 2014-07-10 Vegf拮抗剂治疗早产儿视网膜病变的用途 HK1221231A1 (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361845073P 2013-07-11 2013-07-11
US61/845,073 2013-07-11
PCT/IB2014/063003 WO2015004626A2 (en) 2013-07-11 2014-07-10 Use of a vegf antagonist in treating retinopathy of prematurity

Publications (1)

Publication Number Publication Date
HK1221231A1 true HK1221231A1 (zh) 2017-05-26

Family

ID=51211284

Family Applications (1)

Application Number Title Priority Date Filing Date
HK16109250.8A HK1221231A1 (zh) 2013-07-11 2014-07-10 Vegf拮抗剂治疗早产儿视网膜病变的用途

Country Status (14)

Country Link
US (1) US20160159893A1 (enExample)
EP (1) EP3019527A2 (enExample)
JP (1) JP2016523956A (enExample)
KR (1) KR20160030504A (enExample)
CN (1) CN105377890A (enExample)
AR (1) AR096893A1 (enExample)
AU (3) AU2014288847A1 (enExample)
BR (1) BR112016000282A2 (enExample)
CA (1) CA2917813A1 (enExample)
HK (1) HK1221231A1 (enExample)
MX (1) MX2016000385A (enExample)
RU (1) RU2676303C2 (enExample)
TW (1) TW201536317A (enExample)
WO (1) WO2015004626A2 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3252079B8 (en) 2006-04-07 2020-09-09 Aerpio Therapeutics LLC Antibodies that bind human protein tyrosine phosphatase beta (hptp-beta) and uses thereof
US7622593B2 (en) 2006-06-27 2009-11-24 The Procter & Gamble Company Human protein tyrosine phosphatase inhibitors and methods of use
PL2451279T3 (pl) 2009-07-06 2019-09-30 Aerpio Therapeutics, Inc. Pochodne benzosulfonamidowe, ich kompozycje i ich zastosowanie w zapobieganiu przerzutom komórek nowotworowych
AU2012323856B2 (en) 2011-10-13 2017-05-25 EyePoint Pharmaceuticals, Inc. Methods for treating Vascular Leak Syndrome and cancer
US20150050277A1 (en) 2013-03-15 2015-02-19 Aerpio Therapeutics Inc. Compositions and methods for treating ocular diseases
US9994560B2 (en) 2014-03-14 2018-06-12 Aerpio Therapeutics, Inc. HPTP-β inhibitors
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
US20160144025A1 (en) * 2014-11-25 2016-05-26 Regeneron Pharmaceuticals, Inc. Methods and formulations for treating vascular eye diseases
CN113713101B (zh) 2015-09-23 2023-07-28 视点制药公司 用tie-2的激活剂治疗眼内压的方法
CN108697772B (zh) 2015-12-30 2022-06-24 马歇尔大学科研协会 用于治疗视网膜病的组合物和方法
WO2017117464A1 (en) 2015-12-30 2017-07-06 Kodiak Sciences Inc. Antibodies and conjugates thereof
WO2018017714A1 (en) 2016-07-20 2018-01-25 Aerpio Therapeutics, Inc. HUMANIZED MONOCLONAL ANTIBODIES THAT TARGET VE-PTP (HPTP-ß)
BR112020017872A2 (pt) 2018-03-02 2020-12-22 Kodiak Sciences Inc. Anticorpos de il-6 e construtos de fusão e conjugados dos mesmos
WO2020223209A1 (en) 2019-04-29 2020-11-05 Aerpio Pharmaceuticals, Inc. Tie-2 activators targeting the schlemm's canal
WO2021072265A1 (en) 2019-10-10 2021-04-15 Kodiak Sciences Inc. Methods of treating an eye disorder

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003273299B2 (en) * 2002-09-05 2010-04-01 Medimmune, Llc Methods of preventing or treating cell malignancies by administering CD2 antagonists
MY150740A (en) * 2002-10-24 2014-02-28 Abbvie Biotechnology Ltd Low dose methods for treating disorders in which tnf? activity is detrimental
PL1660057T3 (pl) * 2003-08-27 2012-10-31 Ophthotech Corp Terapia łączona do leczenia zaburzeń związanych z neowaskularyzacją gałki ocznej
WO2005110374A1 (en) 2004-04-30 2005-11-24 Allergan, Inc. Intraocular drug delivery systems containing a therapeutic component, a cyclodextrin, and a polymeric component
AU2006236439B2 (en) * 2005-04-15 2012-05-03 Macrogenics, Inc. Covalent diabodies and uses thereof
WO2007038453A2 (en) * 2005-09-26 2007-04-05 Advanced Ocular Systems Limited Use of an anti-vascular endothelial growth factor (vegf) agent to ameliorate inflammation
US8039010B2 (en) 2006-11-03 2011-10-18 Allergan, Inc. Sustained release intraocular drug delivery systems comprising a water soluble therapeutic agent and a release modifier
KR20210056449A (ko) * 2007-11-07 2021-05-18 안트로제네시스 코포레이션 조산 합병증의 치료에 있어서의 제대혈의 용도
WO2010045506A2 (en) * 2008-10-16 2010-04-22 Kathleen Cogan Farinas Sustained drug delivery system
RU2550258C2 (ru) 2008-11-03 2015-05-10 Молекьюлар Партнерс Аг Связывающие белки, ингибирующие взаимодействия vegf-a рецептора
EP3165606A1 (en) * 2009-05-01 2017-05-10 Ophthotech Corporation Methods for treating or preventing ophthalmological diseases
TWI510246B (zh) 2010-04-30 2015-12-01 Molecular Partners Ag 抑制ｖｅｇｆ－ａ受體交互作用的經修飾結合性蛋白質
RU2469734C2 (ru) * 2010-09-02 2012-12-20 Григорий Владимирович Пантелеев Лечебное средство для лечения расстройств аккомодаций "stiak"
US20140249191A1 (en) * 2011-10-20 2014-09-04 Avienne Pharmaceuticals Gmbh Compositions for Controlling Vascularization in Ophthalmological and Dermatological Diseases
PL2887958T3 (pl) * 2012-08-21 2021-11-22 Opko Pharmaceuticals, Llc Formulacje liposomowe

Also Published As

Publication number Publication date
AU2014288847A1 (en) 2016-01-28
EP3019527A2 (en) 2016-05-18
RU2016104398A3 (enExample) 2018-05-31
WO2015004626A3 (en) 2015-05-28
MX2016000385A (es) 2016-04-29
WO2015004626A2 (en) 2015-01-15
TW201536317A (zh) 2015-10-01
RU2676303C2 (ru) 2018-12-27
AU2019206000A1 (en) 2019-08-01
BR112016000282A2 (pt) 2017-12-12
AR096893A1 (es) 2016-02-03
AU2017204326A1 (en) 2017-07-13
JP2016523956A (ja) 2016-08-12
RU2016104398A (ru) 2017-08-16
KR20160030504A (ko) 2016-03-18
CN105377890A (zh) 2016-03-02
CA2917813A1 (en) 2015-01-15
US20160159893A1 (en) 2016-06-09

Similar Documents

Publication Publication Date Title
HK1221231A1 (zh) Vegf拮抗剂治疗早产儿视网膜病变的用途
MX2016000384A (es) Uso de un antagonista de vegf en el tratamiento de trastornos coriorretinianos neovasculares y de permeabilidad en pacientes pediatricos.
PH12018501325A1 (en) Compositions comprising human milk oligosaccharides for use in infants or young children to prevent or treat a health disorder by increasing glp-1 secretion
WO2014205389A8 (en) Nuclear transport modulators and uses thereof
BR112018069789A2 (pt) medicamento obtido pela combinação do agonista de fxr e arb
HK1223319A1 (zh) 用於治疗或预防眼科病的方法
PH12016500764A1 (en) Compositions for use in the prevention or treatment of urt infections in infants or young children at risk
BR112017002637A2 (pt) métodos para tratar ou prevenir condições oftalmológicas
PH12019500177A1 (en) Treatment and prevention of sleep disorders
BR112018067906A2 (pt) métodos de tratamento de depressão usando antagonistas do receptor de orexina-2
PH12016500732A1 (en) Use of a modified sweet whey and a modified sweet whey containing infant formula for promoting the postnatal development of the infant central nervous system and related cognitive functions
MX2017004658A (es) Sulfatos de colesterol oxigenado para terapia contra trastornos provocados por al menos uno de actividad atenuada de leptina y un trastorno de almacenamiento lipidico.
BR112017024509A2 (pt) tratamento de doença do cns com células de plexo coroide induzíveis encapsulada
PH12018501262A1 (en) Compositions comprising human milk oligosaccharides for use in infants or young children to prevent or treat allergies
WO2014184576A3 (en) Delivery of a therapeutic agent to the cerebral cortex by administering a viral vector by convection enhanced diffusion into the white matter of the brain
NZ744323A (en) Compositions comprising 15-hepe and methods of using the same
PH12017500098A1 (en) Suspension compositions of cyclosporin a for subconjunctival and periocular injection
WO2015031598A3 (en) Therapeutic dnp derivatives and methods using same
Fareed et al. Psychoimmunomodulatory activity of Salvadora persica L.(Miswak) extract on stress model in rats
Fabiani et al. Improving C1 inhibitor deficiency (type 1 and type 2 hereditary angioedema) in Latin America
Karnezi et al. Cognitive behavior drama: an innovative intervention model that combines established psychological methods with the art form of drama to provide young children on the Autism spectrum with the motivation and confidence to overcome their fears
HK1224220A1 (zh) 治疗神经退化性失调的方法
WO2014144731A3 (en) Compositions comprising hypoxia inducible factor-1 alpha and methods of using the same
Committee on Child Health Financing Guiding principles for managed care arrangements for the health care of newborns, infants, children, adolescents, and young adults
Pastore et al. Procedural sedation for intra-articular corticosteroid injections in juvenile idiopathic arthritis (JIA) should be a standard of care